Navigation Links
Newer Blood Thinner May Pose Danger to Trauma Patients
Date:11/23/2011

By Amanda Gardner
HealthDay Reporter

WEDNESDAY, Nov. 23 (HealthDay News) -- A new blood thinner touted for its convenience and enhanced quality of life may have hidden problems that could threaten the lives of certain patients, a new report suggests.

A letter to the editor in the Nov. 24 issue of the New England Journal of Medicine reports severe bleeding complications among trauma patients on the anti-clotting medicine Pradaxa (dabigatran etexilate).

In one case, a patient died, the letter said.

"We have noted on multiple occasions patients who have 'bleeding out' from Pradaxa and our hands are tied," said Dr. Bryan Cotton, lead letter author and a trauma surgeon with the University of Texas Health Science Center at Memorial Hermann Hospital in Houston. "They're bleeding out all over and there's absolutely nothing we can do about it . . . I'm helpless and hopeless when it comes into my emergency room."

The main problem, Cotton said, is that there's no real way to reverse the anti-clotting effect of the drug, unlike older agents such as warfarin.

According to the letter, the only way to reverse Pradaxa is with emergency dialysis but, said Cotton, "in a patient bleeding to death, that's not really a practical or pragmatic option."

Warfarin (Coumadin, Jantoven) has been the mainstay of blood-thinning medications to manage heart and stroke patients for decades.

But the drug is notoriously difficult to manage, requiring frequent lab tests and having interactions with multiple foods and other medications. Its one big advantage, however, is that its blood-thinning properties are easily reversible when needed.

Enter the new, easier-to-use blood thinner, Pradaxa, first approved by the U.S. Food and Drug Administration in late 2010 for use in patients with atrial fibrillation, a common and dangerous form of irregular heartbeat.

"There is an advantage over warfarin in many ways because of the simplicity and ease of management," said Dr. Jack Ansell, chairman of the department of medicine at Lenox Hill Hospital in New York City. "There are very little interactions with other drugs or foods, but once again, warfarin is relatively easily reversible."

Pradaxa also has other problems in addition to the irreversibility, the letter said, namely that there are no readily available tests to assess how well it's working or not working.

"You can't really check the labs. There's no easy, cheap, readily available lab test," Cotton noted.

The information provided in the letter, said Dr. Lisandro Irizarry, chair of emergency medicine at the Brooklyn Hospital Center in New York City, is "incredibly useful and incredibly timely."

"Although this medication provides enhanced quality of life, it does have a significant impact on how we manage patients because there's no way to reverse it and no way to measure how thin the blood is," he said.

Cotton and his co-authors urged the U.S. Food and Drug Administration (FDA) to support more trials to assess the potentially wide-ranging effects of the drug.

"We absolutely understand that it's a lot better for patients from a convenience standpoint . . . but when something goes wrong, it can go wrong very badly," Cotton said.

In a statement, Pradaxa's maker, Boehringer Ingelheim, confirmed that, "At this time, there is no reversal agent available" for the blood thinner. The company says that dialysis can lead to "the removal of about 60 percent of the drug over two to three hours; however, data supporting this approach are limited."

In the meantime, "Patient safety is our top priority and we frequently communicate with the FDA and regulatory agencies around the world to ensure they have the most up-to-date information regarding the safety profile of Pradaxa," the company said. "All treatment decisions should be made on an individual basis between patients and their health care providers and should take into consideration the overall benefits and risks associated with various treatment options."

Pradaxa is not the only new-generation blood thinner to be approved recently -- the anti-clotting drug Brilinta (ticagrelor) gained FDA approval for use in heart patients in July. However, according to Ansell, there is no "reversability" problem with Brilinta.

More information

The U.S. National Library of Medicine has more on blood thinners.

SOURCES: Bryan Cotton, M.D., trauma surgeon and intensivist, Memorial Hermann Hospital and University of Texas Health Science Center, Houston; Lisandro Irizarry, M.D., chair of emergency medicine, Brooklyn Hospital Center, New York City; Jack Ansell, M.D., chairman, department of medicine, Lenox Hill Hospital, New York City; Nov. 23, 2011, statement, Boehringer Ingelheim US, Ridgefield, Conn.; Nov. 24, 2011, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Newer Drug Seems Better at Controlling Lupus Kidney Complication
2. Newer Not Necessarily Better for Football Helmet Design
3. More Evidence Shows Newer Forms of Pill Raise Clot Risk, FDA Says
4. Newer Pill May Raise Blood Clot Risk
5. Newer Contraceptive Pills Could Raise Clot Risk, FDA Warns
6. Are Newer MS Drugs Worth Their High Price Tag?
7. Newer techniques are making cardiac CT safer for children
8. Newer Epilepsy Meds Less Likely to Cause Birth Defects: Study
9. Newer Pill Linked to Higher Risk of Blood Clots
10. Newer Versions of the Pill Pose No Added Risk to Gallbladder
11. UCSF analysis shows newer surgery for neck pain may be better
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newer Blood Thinner May Pose Danger to Trauma Patients
(Date:2/24/2017)... ... February 24, 2017 , ... Houston ... at his office, Antoine Dental Center. Currently, patients can get single dental implants ... apply, but patients can learn more about these offers by contacting Antoine Dental ...
(Date:2/24/2017)... ... February 24, 2017 , ... WHAT: , The New ... opportunities as well as advocacy for the state and region‘s technology businesses, hosted ... The Council's Innovation Forecast event highlights innovation throughout the region from small ...
(Date:2/24/2017)... ... , ... Dr. Ronald E. Hawkins, vice president for academic ... A. Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean of ... comes to Liberty from the Ohio University Heritage College of Osteopathic Medicine (OU-HCOM), ...
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care IT campaign, Robert ... because it’s not if you will be attacked, but when.” However, he and many ... digital health care. , Improvements in auditing and monitoring have taken security in health ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... Healthcare ... The Medical Center at Craig Ranch building at 8080 State Highway 121, Suite 210, ... District with easy access to Highway 121. , As the practice has grown, the ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... CUPERTINO, Calif. , Feb. 24, 2017  In ... fourth quarter 2016 financial results press release, you are ... be broadcast live over the internet on Tuesday, March ... Pacific Time). A live audio webcast of ... at www.durect.com and clicking "Investor Relations."  If ...
(Date:2/24/2017)... 2017 Report analyzes the worldwide markets for Endodontic ... for the US, Canada , ... Asia-Pacific , Latin America , and ... the period 2015 through 2022. Also, a six-year historic analysis ... derived from primary and secondary research. Company profiles are primarily ...
(Date:2/24/2017)... Feb. 23, 2017  This report analyzes the worldwide ... following Products: Intermediates, Analytical, and Others. ... include Pharmaceuticals, and Agrochemicals. The report provides separate comprehensive ... Europe , and Rest of World. ... 2015 through 2022. Also, a six-year historic analysis is ...
Breaking Medicine Technology: